Shares of Evotec SE (NASDAQ:EVO - Get Free Report) fell 2.7% during mid-day trading on Friday . The stock traded as low as $4.67 and last traded at $4.70. 12,596 shares were traded during mid-day trading, a decline of 91% from the average session volume of 133,833 shares. The stock had previously closed at $4.83.
Wall Street Analysts Forecast Growth
A number of analysts recently commented on EVO shares. HC Wainwright restated a "buy" rating and issued a $8.00 price objective on shares of Evotec in a research report on Thursday, November 7th. Jefferies Financial Group downgraded Evotec from a "buy" rating to a "hold" rating and lowered their price target for the stock from $8.70 to $3.80 in a report on Monday, October 7th. Finally, Deutsche Bank Aktiengesellschaft cut Evotec from a "hold" rating to a "sell" rating in a report on Thursday, August 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $5.93.
Check Out Our Latest Report on Evotec
Evotec Price Performance
The stock's 50 day moving average is $3.95 and its two-hundred day moving average is $4.19. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99.
Institutional Investors Weigh In On Evotec
Institutional investors have recently bought and sold shares of the company. Cetera Advisors LLC acquired a new position in shares of Evotec during the 1st quarter worth about $188,000. Vanguard Personalized Indexing Management LLC bought a new position in Evotec in the second quarter valued at approximately $87,000. DCF Advisers LLC increased its position in shares of Evotec by 140.5% during the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company's stock worth $552,000 after purchasing an additional 67,156 shares during the last quarter. Novo Holdings A S bought a new stake in shares of Evotec during the 2nd quarter worth approximately $71,183,000. Finally, Mediolanum International Funds Ltd bought a new position in shares of Evotec in the third quarter valued at $512,000. Institutional investors own 5.81% of the company's stock.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Recommended Stories
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
